Multiple Myeloma News


Here are all the latest news articles written by The Beacon's staff.

For news articles about treatments commonly given to myeloma patients, click on these links:
bisphosphonates, KyprolisPomalyst (Imnovid), Revlimid, thalidomide, Velcade, and Zometa.

For news articles about potential new myeloma treatments, click on these links:
ARRY-520 (filanesib), ACY-1215 (ricolinostat), afuresertib (GSK2110183), BT-062, daratumumab, elotuzumab, ixazomib (MLN9708),  marizomib (NPI-0052), MOR202, oprozomib, panobinostat, SAR650984, Treanda (bendamustine), and Zolinza (vorinostat).

For news articles about specific myeloma-related topics, click on these links:
bone disease, kidney failure, MGUS, maintenance therapy, peripheral neuropathysecondary cancer, smoldering multiple myeloma, and stem cell transplants.


[ by and | Mar 23, 2015 5:27 pm | 7 Comments ]
Additional Treatment To Deepen Response Prior To Transplantation May Not Improve Survival In Newly Diagnosed Multiple Myeloma

A recently published study may change the goals many myeloma special­ists use to make treatment decisions for newly diagnosed myeloma pa­tients planning on having a stem cell transplant.

The study also has potentially broader implications. Indeed, it may influ­ence ongoing debate on a fundamental controversy about how multiple myeloma, in general, should be treated.

The authors of the new study looked at data for 539 myeloma patients who failed to achieve even a partial response to their initial (induction) treat­ment regimen after diagnosis.

After their initial treatment failed, some of the …

Read the full story »
[ by | Mar 10, 2015 9:24 am | 6 Comments ]
Common Chromosomal Abnormalities Occur Less Often In African-American Than White Multiple Myeloma Patients

The results of a recently published study show that, among newly diag­nosed myeloma patients, African-Americans are less likely than white Americans to have the four most common myeloma-related chro­mo­somal ab­nor­mal­ities.

The authors of the study investigated how often the chro­mo­somal ab­nor­mal­ities t(11;14), t(4;14), del(13q), and del(17p) were present in two dif­fer­ent groups of newly diagnosed myeloma patients. One group con­sisted of African-Americans, the other of white Americans.

Each of the four ab­nor­mal­ities occurred less frequently in the African-American patients.

In addition, almost two-thirds of the African-American patients (63 per­cent) did …

Read the full story »
[ by | Mar 3, 2015 10:36 pm | 7 Comments ]
High-Dose Kyprolis Extends Progression-Free Survival Versus Velcade In Head-To-Head Relapsed Myeloma Trial

Initial results of a large, head-to-head clinical trial show that relapsed myeloma patients treated with high-dose Kyprolis and dex­a­meth­a­sone had twice the progression-free survival of relapsed patients treated with Velcade and dex­a­meth­a­sone.

Median progression-free survival in the Phase 3 trial was 18.7 months in trial participants treated with high-dose Kyprolis (carfilzomib) and dex­a­meth­a­sone (Decadron), compared to 9.4 months in patients treated with Velcade (bor­tez­o­mib) and dex­a­meth­a­sone.

The results of the so-called “ENDEAVOR” trial were announced this past Sunday evening in a press release issued …

Read the full story »
[ by | Feb 26, 2015 7:40 pm | 3 Comments ]
Farydak – Questions & Answers About The FDA Approval

The U.S. Food and Drug Administration (FDA) on Monday approved Farydak (panobinostat) for the treatment of multiple myeloma (see related Beacon news).

Since the FDA announced its decision, multiple myeloma patients, care­givers, and health care professionals have been asking a number of important questions about Farydak. This article compiles many of those questions and provides answers to them.

The information in this article is based primarily on the official, FDA-approved prescribing information for Farydak. In addition, The Beacon has received feedback in regard to …

Read the full story »
[ by | Feb 23, 2015 3:30 pm | 13 Comments ]
FDA Approves Farydak (Panobinostat) For The Treatment Of Relapsed Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has approved panobinostat, which will be marketed under the brand name Farydak, for the treatment of relapsed and refractory multiple myeloma.

Specifically, Farydak has been approved for use in combination with Velcade (bortezomib) and dexamethasone (Decadron) in patients with multiple myeloma who have received at least two prior standard therapies.

The two prior therapies must include Velcade and at least one treatment from the immunomodulatory class of drugs, which includes Revlimid (lenalidomide), thalidomide, and Pomalyst …

Read the full story »
[ by | Feb 18, 2015 7:43 pm | 2 Comments ]
FDA Broadens Revlimid's Approved Use To Include Newly Diagnosed Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has ex­panded the of­ficial­ly ap­proved use of Revlimid to include the treat­ment of newly diag­nosed multiple myeloma.

Previously, Revlimid’s approval in the U.S. and elsewhere in the world was for the treat­ment of myeloma patients who have re­ceived at least one prior therapy.

With the expanded U.S. approval, there no longer is any re­striction regard­ing prior therapies in the FDA-approved pre­scrib­ing in­for­ma­tion for Rev­limid (lena­lido­mide).

The new edition of the pre­scrib­ing in­for­ma­tion says simply that “Revlimid in combination with dexa­metha­sone is …

Read the full story »